Merck KGaA to Acquire Bio-Techne for $11.3 Billion

German pharmaceutical and life sciences company Merck KGaA has agreed to acquire U.S.-based Bio-Techne in a cash deal valued at approximately $11.3 billion, representing a significant expansion of its product portfolio.

By Colleen Cabili Fri, June 26, 2026 at 5:13 PM GMT+3 2 min read · Yahoo Finance · June 26, 2026, 14:13 UTC

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

Tickers: $TECH

Topics: acquisition life sciences pharmaceuticals

Read the full article at Yahoo Finance

More World news

Pomerantz Law Firm Investigates Boston Scientific Following Q3 Earnings Miss and Guidance Downgrade PR Newswire · November 12, 2026, 15:35 UTC
Jensen Huang Concludes 33-Year Tenure as CEO of Nvidia Seeking Alpha · November 12, 2026, 15:29 UTC
Metalla Royalty & Streaming Reports Q3 Revenue Growth and Increased Adjusted EBITDA Seeking Alpha · November 12, 2026, 15:26 UTC
Fed Governor Michael Barr Warns AI Market Concentration Could Drive Income Inequality Seeking Alpha · November 12, 2026, 15:27 UTC
Jefferies Upgrades Pattern Group (PTRN) Following Strong Brand Acquisition Performance Seeking Alpha · November 12, 2026, 15:27 UTC
Pomerantz Law Firm Investigates Six Flags Entertainment Corporation Following Fatal Roller Coaster Accident PR Newswire · November 12, 2026, 15:30 UTC
SpaceX Partners with Qualcomm to Launch Starlink Mobile Cellular Service Motley Fool · November 12, 2026, 15:21 UTC
Blast Resources Appoints Andy Yackulic as CEO to Lead Uranium Exploration PR Newswire · November 12, 2026, 15:26 UTC
FMC Corporation Shares Decline 13% in Thursday Trading Seeking Alpha · November 12, 2026, 15:22 UTC
U.S. Stock Indices Decline Following Nvidia CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 15:23 UTC